BioMelbourne Network
Progressing BioIndustry

News and Opinions

Previous1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9

2015

April

Invion Limited $4.1 Million Entitlement Offer Fully Subscribed Further $1.3 Million Placement Completed

22 April 2015.  On 20 March 2015, Invion Limited (ASX: IVX) announced a 2 for 7, fully underwritten, non-renounceable Entitlement Offer for ordinary shares at an offer price of $0.025 (Entitlement Offer) to raise approximately $4.1 million, following on from its successful placement at the same price per share for a total capital raise of $5.0 million. Invion today is pleased to announce that t... read more…

Phosphagenics Initiates Oxycodone Patch Dosing in Phase 2 Clinical Trial

17 April 2015.  Australian drug delivery company Phosphagenics Limited (ASX:POH; OTCQX:PPGNY) has commenced dosing in its Phase 2 TPM®/Oxycodone patch trial (POH 035-13). Study POH 035-13 is a double-blind, randomised, cross-over Phase 2 clinical trial investigating the safety and efficacy of Phosphagenics’ TPM®/Oxycodone patch in up to 28 patients suffering post herpetic neuralgia (PHN).   Re... read more…

FDA Confirms Change of Ownership of 23 US Generic Drugs and IDT Successfully Manufactures First Batch of Tablets

13 April 2015.  IDT Australia Limited (IDT.AX) announces that the US Food and Drug Administration (FDA) has confirmed receipt of the change of ownership letters formally transferring ownership of the 23 generic drug products to IDT.   Formalising change of ownership is a process whereby the vendor and the purchaser both submit correspondence informing the FDA that the transfer of a drug regis... read more…

Phosphagenics Appoints Three New Directors

13 April 2015.  Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), announces that it has appointed three new directors to The Board. The new directors include Dr Greg Collier, Mr Peter Lankau and the Company’s recently appointed CEO, Dr Ross Murdoch.Dr Greg Collier is currently the CEO of ASX listed company Invion Ltd, and has more than 20 years’ experience spanni... read more…
March

Trajan and University of Tasmania Secure Top Postdoctoral Fellows for ASTech

27 March 2015.  Trajan Scientific and Medical (Trajan) and University of Tasmania (UTAS) are delighted to secure three top scientists to oversee innovative research programs at ASTech, the ARC Training Centre for Portable Analytical Separation Technologies, supported by the Australian Research Council (ARC).ASTech is a collaboration between Trajan and UTAS combining industry knowledge and resea... read more…

LBT Granted First U.S. Patent for APAS® Technology

26 March 2015.  Australian medical technology company LBT Innovations Limited (ASX: LBT) has been awarded the first U.S. patent for its pioneering culture-plate analysis technology, the Automated Plate Assessment System (APAS®).Patent no. 8,896,706 relates to a novel method for ‘colour calibrating’ images captured by the APAS technology, which will make it easier for devices using APAS to accur... read more…

Employee Share Scheme reforms introduced into Parliament

26 March 2015.  The following information has been provided by EY regarding the introduction of Employee Share Scheme reforms into Parliament: Following the proposed reforms to the employee share scheme (ESS) rules announced on 14 October 2014, and a consultation process on the draft legislation last month, the Bill was introduced into Parliament this week. The key reforms contained in the B... read more…

Phosphagenics signs license agreement to expand TPM®-based animal nutrition products to the UK and Ireland.

25 March 2015.  Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), announced that it has granted Integrated Animal Health (IAH) a four year exclusive license to manufacture and sell animal nutrition products that incorporate the Company’s proprietary vitamin E phosphate technology (TPM®). The products, which will be marketed under IAH’s Feed-Mate™ brand, target re... read more…

Dr Bronwyn Evans to Chair Industry Growth Centre for Medical Technologies and Pharmaceuticals

23 March 2015.  Dr Bronwyn Evans, Chief Executive Officer of Standards Australia, has been appointed as Chair of the Industry Growth Centre for Medical Technologies and Pharmaceuticals by Commonwealth Minister for Industry and Science Ian Macfarlane MP. The Australian government has allocated $188.5 million to establish five Industry Growth Centres in key growth sectors: advanced manufacturing;... read more…

Invion $5 Million Private Placement & Rights Issue

20 March 2015.  Australian drug development company Invion Limited (ASX: IVX) is pleased to announce that it has successfully raised $895,000 in a private placement to institutional and sophisticated investors and will now raise a further $4.1 million in a fully underwritten non-renounceable rights issue to existing shareholders.The institutional placement is for approximately 35.8 million full... read more…